The circulation In: RangHPDaleMM, eds. Pharmacology. New York: Churchill Livingstone, 1991: 346–68.
3.
WaeberBGavrasIBrunnerHRCookCACharacoposFGavrasH. Prediction of sustained antihypertensive efficacy of chronic Captopril therapy: relationships to immediate blood pressure response and control plasma renin activity. Am Heart J1982; 103: 384–90.
4.
Losartan for hypertension. Med Lett1995; 37: 57–8.
5.
HanssonL. The future role of losartan. J Hum Hypertens1995; 9 (suppl 5): S55–8.
6.
VelasquezMT. Angiotensin II receptor blockers. A new class of antihypertensive drugs. Arch Fam Med1996; 5: 351–6.
7.
KrichbaumPAbramowitzB. Focus on losartan: an angiotensin II receptor antagonist for the treatment of hypertension. Hosp Form1994; 29: 683–96.
8.
MayBDYoungLYWiserTH. Essential hypertension. In: Koda-KimbleMAYoungLY, eds. Applied therapeutics: the clinical use of drugs. Vancouver, WA: Applied Therapeutics, Inc., 1992: 7-2–7-27.
9.
TimmermansPBCariniDJChiuATDunciaJVPriceWAJrWellsGJ. The discovery of a new class of highly specific nonpeptide angiotensin II receptor antagonists. Am J Hypertens1991; 4: 275s–81s.
10.
BurnierMWaeberBBrunnerHR. The advantage of angiotensin II antagonism. J Hypertens1994; 12 (suppl 2): S7–15.
11.
ChristenYWaeberBNussbergerJShumLBrunnerJBrunnerH. Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Circulation1991; 83: 1333–42.
12.
ChiuATMcCallDEPriceWA. Nonpeptide angiotensin II receptor antagonist. VII. Cellular and biochemical pharmacology of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther1990; 252: 711–8.
13.
RhalebNERouissiNNantelFD'Orleans-JustePRegoliD. DuP 753 is a specific antagonist for the angiotensin receptor. Hypertension1991; 17: 480–4.
14.
AwanNAMasonDT. Direct selective blockade of the vascular angiotensin II receptors in the therapy for hypertension and severe congestive heart failure. Am Heart J1996; 131: 177–85.
15.
TownsendRHaggertBLissCEdelmanJM. Efficacy and tolerability of losartan versus enalapril alone or in combination with hydrochlorothiazide in patients with essential hypertension. Clin Ther1995; 17: 911–23.
16.
NelsonEMerrillDSweetCBradstreetTPanebiancoDByynyR. Efficacy and safety of oral MK-954 (DuP 753), an angiotensin receptor antagonist, in essential hypertension (abstract). J Hypertens1991; 9 (suppl 6): S468–9.
17.
GoldbergMRBradestreetTEMcWilliamsEJTanekaWKLipertSBjornssonTD. Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients. Hypertension1995; 25: 37–46.
18.
GradmanAHArcuriKEGoldbergAIIkedaLSNelsonEBSnavelyDB. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension1995; 25: 1345–50.
19.
The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med1993; 153: 154–83.
20.
LacourciereYBrunnerHIrwinRKarlbergBERamsayLESnavelyDB. Effects of modulators of the renin-angiotensin-aldosterone system on cough. J Hypertens1994; 12: 1387–93.
21.
GoldbergAIDunlayMCSweetCS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol1995; 75: 793–5.
22.
ASHP therapeutic guidelines on angiotensin-converting enzyme inhibitors in patients with left ventricular dysfunction. Am J Health-Syst Pharm1997; 54: 299–313.
23.
DicksteinKChangPWilienheimerRHaunsøSRemesJHallC. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. J Am Coll Cardiol1995; 26: 438–45.
24.
GottliebSDicksteinKFleckEKostisJLevineTBLeJemtelT. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation1993; 88 (part 1): 1602–9.
25.
CrozierIIkramHAwanNClelandJStephenNDicksteinK. Losartan in heart failure. Circulation1995; 91: 691–7.
26.
RavidMSavinHJutrinIBentalTKatzBLishnerM. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med1993; 118: 577–81.
27.
LewisEHunsickerLGBainRP, Rohde RD, for The Collaborative Study Group. The effects of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med1993; 329: 1456–62.
28.
VibertiGMogensenCEGroopLC, Pauls, JF, for the European Microalbuminuria Captopril Study Group. Effect of Captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA1994; 271: 275–9.
29.
GansevoortRTde ZeeuwDShahinfarSRedfieldAde JongPE. Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease. J Hypertens1994; 12 (suppl 2): S37–42.
30.
JoverBMimranA. Angiotensin II receptor antagonist versus angiotensin converting enzyme inhibitors: effects on renal function. J Hypertens1994; 12 (suppl 9): S3–9.
31.
AckerCGGreenbergA. Angioedema induced by the angiotensin II blocker losartan (letter). N Engl J Med1995; 333: 1572.
32.
BeischerNAMackayEVObstetrics and the newborn. Philadelphia: WB Saunders Co., 1986: 389–98.
33.
National Center for Health Statistics. Natality. In: Vital statistics of the United States, 1990, Vol. 1. Washington, DC: Public Health Service, 1994.
34.
WingDAJonesMMRahallAGoodwinTMPaulRH. A comparison of misoprostol and prostaglandin E2 gel for preinduction cervical ripening and labor induction. Am J Obstet Gynecol1995; 172: 1804–10.
35.
American hospital formulary service drug information 1996. Bethesda, MD: American Society of Health-System Pharmacists, 1996: 2370–1.
36.
GaugerLJ. Extemporaneous preparation of a dinoprostone gel for cervical ripening. Am J Hosp Pharm1983; 40: 2195–6.
37.
Package insert. Prostin E2 (dinoprostone). Kalamazoo, MI: The Upjohn Co., June 1992.
38.
KelseyJJPrevostRR. Drug therapy during labor and delivery. Am J Hosp Pharm1994; 51: 2394–402.
MarguliesMPerezGA CamposVotoLS. Misoprostol to induce labor (letter). Lancet1992; 339: 64.
45.
FletcherHMMitchellSSimeonDFrederickJBrownD. Intravaginal misoprostol as a cervical ripening agent. Br J Obstet Gynaecol1993; 100: 641–4.
46.
FletcherHMMitchellSFrederickJSimeonDBrownD. Intravaginal misoprostol versus dinoprostone as cervical ripening and labor-inducing agents. Obstet Gynecol1994; 83: 244–7.
47.
WingDARahallAJonesMMGoodwinTMPaulRH. Misoprostol: an effective agent for cervical ripening and labor induction. Am J Obstet Gynecol1995; 172: 1811–6.
48.
ChuckFJHuffakerBJ. Labor induction with intravaginal misoprostol versus intracervical prostaglandin E2 gel (Prepidil gel): randomized comparison. Am J Obstet Gynecol1995; 173: 1137–42.
49.
VaraklisKGuminaRStubblefieldPG. Randomized controlled trial of vaginal misoprostol and intracervical prostaglandin E2 gel for induction of labor at term. Obstet Gynecol1995; 86: 541–4.
50.
WingDAPaulRH. A comparison of differing dosing regimens of vaginally administered misoprostol for preinduction cervical ripening and labor induction. Am J Obstet Gynecol1996; 175: 158–64.
51.
MundleWRYoungDC. Vaginal misoprostol for induction of labor: a randomized controlled trial. Obstet Gynecol1996; 88: 521–5.
52.
BerkowRFletcherAJBondyPKDiltsPVDouglasRGDrossmanDA., eds. The Merck manual of diagnosis and therapy. Rahway, NJ: Merck Research Laboratories, 1992.
53.
DoverGJCharacheS. Hydroxyurea induction of fetal hemoglobin synthesis in sickle-cell disease. Semin Oncol1992; 19 (suppl 9): 61–6.
54.
YarbroJW. Mechanism of action of hydroxyurea. Semin Oncol1992; 19 (suppl 9): 1–10.
55.
McEvoyGK, ed American Hospital Formulary Service drug information. Bethesda, MD: American Society of Health-System Pharmacists, 1996: 766.
56.
CharacheS. Fetal hemoglobin, sickling, and sickle cell disease. In: BarnessLA, ed. Advanced pediatrics. St. Louis: Mosby Year Book, 1990: 1–31.
57.
RodgersGP. Spectrum of fetal hemoglobin responses in sickle cell patients treated with hydroxyurea: the National Institutes of Health experience. Semin Oncol1992; 19 (suppl 9): 67–73.
58.
GoldbergMABrugnaraCDoverGJSchapiraLLacroixLBunnHF. Hydroxyurea and erythropoietin therapy in sickle cell anemia. Semin Oncol1992; 19 (suppl 9): 74–81.
59.
RodgersGPDoverGJUyesakaNNoguchiCTSchecterANNienhuisAW. Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease. N Engl J Med1993; 328: 73–80.
60.
CharacheSTerrinMLMooreRDDoverGJBartonFBEckertSV. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med1995; 322: 1317–22.
61.
FersterAVermylenCCornuGBuyseMCorazzaFDevalckC. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood1996; 88: 1960–4.
62.
El-HazmiMAFAl-MomenAKandaswamySHuraibSHarakatiMAl-MoharebF. On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease. Acta Haematol1995; 94: 128–34.
63.
CharacheS. Clinical alert: drug treatment for sickle cell anemia. Bethesda, MD: The National Heart, Lung, and Blood Institute, January 1995.
